Role of Fibulin-1 in APP Processing
Fibulin-1 在 APP 处理中的作用
基本信息
- 批准号:8702067
- 负责人:
- 金额:$ 14.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-08-01 至 2015-07-31
- 项目状态:已结题
- 来源:
- 关键词:Abeta synthesisAddressAlkaline PhosphataseAlzheimer&aposs DiseaseAmyloid beta-ProteinAmyloid beta-Protein PrecursorAmyloid depositionBehaviorBindingBrainCellsCognitiveConditioned Culture MediaDementiaDevelopmentDisintegrinsEmbryoEngineeringEnzymesEpidermal Growth FactorEtiologyEventExtracellular Matrix ProteinsFamilyFibroblastsFunctional disorderGene DeletionGoalsHeparin BindingKnockout MiceLeadMediatingMembraneMetalloproteasesMusNeuregulin 1NeuroblastomaNeurodegenerative DisordersNeuronsPathogenesisPhorbol EstersPlayProcessProductionProteolysisProteolytic ProcessingRoleSenile PlaquesSmall Interfering RNATestingTherapeuticTherapeutic InterventionTransgenic MiceTransgenic Organismsalpha secretaseamyloid precursor protein processingbasebeta secretasebrain cellcellular engineeringcombatfibulin 1gamma secretaseinhibitor/antagonistinterestmemberoverexpressionpeptide Apublic health relevancesecretasetherapeutic target
项目摘要
DESCRIPTION (provided by applicant): Many current pharmacological approaches to combating Alzheimer's disease (AD) seek to block Abeta production through inhibition of the amyloidogenic enzymes known as beta- and gamma-secretases. An alternative approach is to activate the alpha-secretase processing of amyloid precursor protein (APP), which is mediated by several members of the disintegrin family of metalloproteases, ADAM9, ADAM10 and ADAM17. Processing of APP by these alpha-secretases is thought to be beneficial with respect to AD since it limits production of Abeta and generates the neuroprotective soluble APPalpha (sAPPalpha) product. Fibulin-1 (Fbln1) is an extracellular matrix protein, expressed in the brain by neurons, that binds the amino terminus of APP and sAPPalpha. The significance of this interaction is not yet established however, we have found that Fbln1 also binds to other membrane anchored alpha-secretase substrates, heparin binding-epidermal growth factor (HB-EGF) and neuregulin-1 (NRG1). We also show that Fbln1 acts to inhibit the proteolytic release of soluble forms of HB-EGF and NRG1. Furthermore, we have found increased levels of sAPPalpha in the conditioned culture medium of Fbln1 null mouse embryo fibroblasts (MEFs) as compared to wildtype MEFs. Based on these findings it is hypothesized that Fbln1 serves as an inhibitor of alpha-secretase processing of APP and therefore may represent a therapeutic target that if inhibited might lead to augmented alpha-secretase processing of APP and reduced pathological APP cleavage. To address this hypothesis there are three specific aims: 1) Determine whether brain APP proteolytic cleavage is altered in Fbln1-deficient mice, 2) determine whether transgenic overexpression of Fbln1 accelerates Abeta production and exacerbates AD pathogenesis, and 3) determine whether Fbln1 inhibits alpha-secretase processing of APP in cultured neuronal cells.
描述(申请人提供):目前许多抗击阿尔茨海默病(AD)的药理学方法寻求通过抑制淀粉样蛋白生成酶(称为β-和伽马-分泌酶)来阻止Abeta的产生。另一种方法是激活淀粉样前体蛋白(APP)的α-分泌酶处理,这是由金属蛋白去整合素家族的几个成员ADAM9、ADAM10和ADAM17介导的。通过这些α-分泌酶处理APP被认为对AD是有益的,因为它限制了Abeta的产生,并产生了神经保护性的可溶性APPalpha(SAPPalpha)产物。纤维蛋白-1(Fbln1)是一种细胞外基质蛋白,由神经元表达,与APP和sAPPalpha的氨基末端结合。然而,我们发现Fbln1还与其他膜锚定的α-分泌酶底物--肝素结合-表皮生长因子(HB-EGF)和神经调节蛋白-1(NRG1)结合。我们还发现,Fbln1可以抑制可溶性形式的HB-EGF和NRG1的蛋白水解性释放。此外,我们还发现,与野生型小鼠胚胎成纤维细胞相比,Fbln1缺失的小鼠胚胎成纤维细胞的条件培养液中sAPPalpha的水平增加。根据这些发现,推测Fbln1是APPα-分泌酶加工的抑制剂,因此可能是一个治疗靶点,如果被抑制,可能会导致APPα-分泌酶加工的增强和病理性APP切割的减少。为了解决这一假说,有三个具体的目的:1)确定Fbln1基因缺陷小鼠脑内APP蛋白水解酶是否发生改变,2)确定Fbln1转基因过表达是否加速Abeta的产生并加剧AD的发病,以及3)确定Fbln1是否抑制培养的神经细胞中APP的α-分泌酶处理。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KELLEY M ARGRAVES其他文献
KELLEY M ARGRAVES的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KELLEY M ARGRAVES', 18)}}的其他基金
S1P Deficiency Prolongs Endothelial Barrier Recovery After Fontan Operation
S1P 缺乏可延长 Fontan 手术后内皮屏障的恢复
- 批准号:
8444397 - 财政年份:2012
- 资助金额:
$ 14.69万 - 项目类别:
S1P Deficiency Prolongs Endothelial Barrier Recovery After Fontan Operation
S1P 缺乏可延长 Fontan 手术后内皮屏障的恢复
- 批准号:
8302043 - 财政年份:2012
- 资助金额:
$ 14.69万 - 项目类别:
HDL-Associated S1P as an Indicator of Relative Risk for Cardiovascular Disease
HDL 相关 S1P 作为心血管疾病相对风险的指标
- 批准号:
7739654 - 财政年份:2009
- 资助金额:
$ 14.69万 - 项目类别:
HDL-Associated S1P as an Indicator of Relative Risk for Cardiovascular Disease
HDL 相关 S1P 作为心血管疾病相对风险的指标
- 批准号:
7904887 - 财政年份:2009
- 资助金额:
$ 14.69万 - 项目类别:
SC COBRE: SPHINGOSINE1PHOSPHATE IN EARLY BLOOD VESSEL FORMATION
SC COBRE:早期血管形成中的磷酸鞘氨醇
- 批准号:
7610441 - 财政年份:2007
- 资助金额:
$ 14.69万 - 项目类别:
SC COBRE: SPHINGOSINE1PHOSPHATE IN EARLY BLOOD VESSEL FORMATION
SC COBRE:早期血管形成中的磷酸鞘氨醇
- 批准号:
7381846 - 财政年份:2006
- 资助金额:
$ 14.69万 - 项目类别:
Sphingosine-1-phosophate signaling in vasculogenesis
1-磷酸鞘氨醇信号传导在血管发生中的作用
- 批准号:
6908722 - 财政年份:2005
- 资助金额:
$ 14.69万 - 项目类别:
SC COBRE: SPHINGOSINE1PHOSPHATE IN EARLY BLOOD VESSEL FORMATION
SC COBRE:早期血管形成中的磷酸鞘氨醇
- 批准号:
7171076 - 财政年份:2005
- 资助金额:
$ 14.69万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 14.69万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 14.69万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 14.69万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 14.69万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 14.69万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 14.69万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 14.69万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 14.69万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 14.69万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 14.69万 - 项目类别:
Research Grant